Teva wins US FDA approval for Xgeva biosimilar DEGEVMA

Bitget2026/09/28 20:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Teva won FDA clearance for DEGEVMA (denosumab-adet), a biosimilar to Amgen’s Xgeva.
Label covers Xgeva’s full uses, including prevention of bone complications in advanced cancer with bone metastases.
Approval follows March 2026 FDA clearance of PONLIMSI, giving Teva a U.S. denosumab biosimilar portfolio across Xgeva, Prolia.
U.S. launches for DEGEVMA, PONLIMSI expected in coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609281600PRIMZONEFULLFEED1001275047) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Teva wins US FDA approval for Xgeva biosimilar DEGEVMA

You may also like

Crypto prices